Ultrasound Deficiencies in MASLD-Related Cirrhosis Surveillance
Ultrasound remains the primary screening test for hepatocellular carcinoma (HCC) among patients with cirrhosis, but the method exhibits limited sensitivity in metabolic dysfunction-associated steatotic liver disease (MASLD). As findings discussed at The Liver Meeting 2026 in Denver, Colorado, obesity and steatosis frequently obscure the ultrasound signal in MASLD-related cases. Experts estimate that a quarter to a third of all ultrasounds performed in patients with MASLD yield low diagnostic quality.
Radiologists utilize grading systems from A to C to evaluate ultrasound quality, with category C designating poor scans. Clinical protocols recommend repeating a poor-quality ultrasound once, potentially with a different operator, before shifting to alternative imaging modalities. After two poor-quality scans, clinicians should transition patients to computed tomography (CT) or magnetic resonance imaging (MRI). While CT provides an alternative option, it carries a substantial radiation load, so MRI is the other option.
Investigative abbreviated MRI awaits stronger supporting data
Conventional MRI remains the imaging modality most people use, whereas abbreviated MRI remains an investigative technique still being tested for this purpose. Early results for abbreviated MRI show promise, but widespread clinical adoption awaits stronger supporting data. Meanwhile, observational datasets indicate that statins, glucagon-like peptide-1 (GLP-1) receptor agonists, and metformin correlate with a lower risk of developing HCC.
Observational cohorts and case-control studies strengthen these protective signals, yet definitive verification requires randomized controlled trials. Clinical trials evaluating GLP-1 receptor agonists and statins in patients with cirrhosis are currently active, though no trials of metformin are known. Clinicians currently prescribe these medications primarily for underlying indications—such as cardiovascular risk reduction for statins, metabolic dysfunction-associated steatohepatitis (MASH) treatment for GLP-1 receptor agonists, and prediabetes management for metformin—while any additional benefit in terms of reducing liver cancer risk can be secondary or a cofactor.
Risk Stratification in Noncirrhotic F3 Fibrosis
Up to 30% of MASLD-related hepatocellular carcinoma cases develop in patients who lack recognized cirrhosis, according to findings discussed at The Liver Meeting 2026. Because hundreds of millions of individuals globally live with noncirrhotic MASLD, universal surveillance proves inefficient and impractical. Patients with F3 fibrosis represent an intermediate subgroup exhibiting an elevated cancer risk compared to the broader noncirrhotic population, drawing increased clinical attention.
Clinical decision-making for F3 surveillance incorporates metabolic risk factors such as diabetes, obesity, hypertension, and dyslipidemia, alongside genetic testing panels evaluating high-risk variants of the PNPLA3 gene. Emerging risk calculators aim to synthesize age, genetics, metabolic parameters, and alcohol consumption into unified equations to divide noncirrhotic patients into higher- and lower-risk categories.
Alcohol approximately doubles liver cancer risk
Data indicate that alcohol approximately doubles liver cancer risk in this combined patient population.
Accurate capture of alcohol intake history remains difficult in routine clinical practice, necessitating systematic screening tools such as the Alcohol Use Disorders Identification Test–Consumption (AUDIT-C).
Frequently Asked Questions About MASLD Surveillance and Treatment
Why does ultrasound perform poorly for HCC surveillance in MASLD patients?
Obesity and hepatic steatosis obscure the ultrasound signal, causing some ultrasounds in MASLD patients to yield low diagnostic quality.
What threshold prompts a switch from ultrasound to MRI for liver cancer screening?
Clinicians typically repeat a poor-quality ultrasound once, but after two poor-quality scans, shifting to an alternative imaging modality like MRI is recommended.
How does F3 fibrosis alter hepatocellular carcinoma risk without cirrhosis?
Up to 30% of MASLD-related liver cancers develop without recognized cirrhosis, and patients with F3 fibrosis exhibit a higher cancer risk than the rest of the noncirrhotic population, particularly when metabolic risk factors are present.
What is MetALD and how does it affect liver cancer risk?
MetALD occurs when patients with metabolic dysfunction consume alcohol, roughly doubling their overall risk of developing liver cancer.
Worth a look